Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations

[1]  Shaji K. Kumar,et al.  The multiple myelomas — current concepts in cytogenetic classification and therapy , 2018, Nature Reviews Clinical Oncology.

[2]  G. Morgan,et al.  Hyperhaploid karyotypes in multiple myeloma , 2017, Oncotarget.

[3]  Pingping Qu,et al.  The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma , 2017, Haematologica.

[4]  B. Barlogie,et al.  Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma , 2017, Leukemia.

[5]  Shaji K. Kumar,et al.  Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. , 2017, Blood advances.

[6]  R. Fonseca,et al.  Trends in overall survival and costs of multiple myeloma, 2000–2014 , 2016, Leukemia.

[7]  S Vincent Rajkumar,et al.  Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management , 2016, American journal of hematology.

[8]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[9]  D. Rossi,et al.  Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature , 2016, Oncotarget.

[10]  M. Mohty,et al.  Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? , 2015, Blood.

[11]  H. Goldschmidt,et al.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Gordon Cook,et al.  Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Dimopoulos,et al.  Staging and prognostication of multiple myeloma , 2014, Expert review of hematology.

[14]  L. Campbell,et al.  Hyperhaploid plasma cell myeloma. , 2012, Cancer genetics.

[15]  B. Johansson,et al.  Disease‐associated patterns of disomic chromosomes in hyperhaploid neoplasms , 2012, Genes, chromosomes & cancer.

[16]  A. Al-Katib,et al.  Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes , 2007, American journal of hematology.

[17]  N. Pandis,et al.  Cytogenetic manifestations of multiple myeloma heterogeneity , 2005, Genes, chromosomes & cancer.

[18]  C. Bastard,et al.  Hypodiploidy is a major prognostic factor in multiple myeloma. , 2001, Blood.

[19]  R. Advani,et al.  Series THE UPDATED WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES The 2016 revision of the World Health Organization classi fi cation of lymphoid neoplasms , 2016 .